INCB052793

Generic Name: INCB052793

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

First Posted Date: 2019-04-08

Last Posted Date: 2019-04-08

Lead Sponsor: Incyte Corporation

Registration Number: NCT03906344

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Malignancies
Solid Tumors
Metastatic Cancer

Interventions: Drug: azacitidine
Drug: INCB052793
Drug: gemcitabine
Drug: nab-paclitaxel
Drug: INCB039110
Drug: dexamethasone
Drug: Carfilzomib
Drug: bortezomib
Drug: lenalidomide
Drug: pomalidomide
Drug: INCB050465

First Posted Date: 2014-10-16

Last Posted Date: 2020-04-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT02265510

Locations: 🇺🇸
Site 2, Nashville, Tennessee, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy